Scholars@Duke
Christopher Hoimes

Christopher Hoimes

Instructor in the Department of Medicine
Medicine, Medical Oncology
christopher.hoimes@duke.edu
905 S LaSalle St, DUMC 103861 ; Rm 2010, Durham, NC 27710

Selected Publications

Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.

Journal Article Oncologist · November 11, 2025 BACKGROUND: Erdafitinib is approved for locally advanced/metastatic urothelial cancer (LA/mUC). As enfortumab vedotin (EV) plus pembrolizumab enters frontline management, outcomes with erdafitinib pre- and post-EV are clinically relevant but not specifical ... Full text Link to item Cite

Abstract B006: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC)

Conference Molecular Cancer Therapeutics · October 22, 2025 AbstractBackground:XmAb819 is a T-cell engaging bispecific antibody in development for patients with ccRCC. Despite advances in ... Full text Cite

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.

Journal Article Clin Cancer Res · October 1, 2025 PURPOSE: Nelitolimod (previously SD-101) is a toll-like receptor 9 agonist. We assessed whether intratumoral nelitolimod plus pembrolizumab potentiates antitumor activity in patients with advanced melanoma who had not previously received anti-PD-1/PD-L1 th ... Full text Link to item Cite

Supplementary Table S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <p>Table S3 reports PFS for patients with anti–PD-1/PD-L1–naive melanoma who received nelitolimod 2 mg or 8 mg and pembrolizumab 200 mg (intention-to-treat).</p> ... Full text Cite

Supplementary Figure S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <p>Figure S1 shows the treatment schema with nelitolimod 2 mg or 8 mg and pembrolizumab 200 mg. Nelitolimod was administered weekly for 4 weeks, followed by one dose every 3 weeks for up to 22 doses.</p> ... Full text Cite

Supplementary Figure S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <p>Figure S2 shows detailed response and treatment duration data for patients with anti–PD-1/PD-L1–naive melanoma treated with nelitolimod 2 mg plus pembrolizumab 200 mg. The figure illustrated patterns of tumor response over time.</p>< ... Full text Cite

Supplementary Figure S6 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <p>Figure S6 shows transcriptomic data from paired tumor biopsies collected at baseline and on therapy from patients treated with nelitolimod 2 mg plus pembrolizumab 200 mg. The figure displays consistent and durable increases in the expressi ... Full text Cite

Supplementary Figure S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <p>Figure S3 shows best percentage changes from baseline in target lesion size, grouped by PD-L1 status, for patients treated with nelitolimod 8 mg plus pembrolizumab 200 mg. The plot highlights greater tumor shrinkage in patients with PD-L1– ... Full text Cite

Supplementary Figure S4 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <p>Figure S4 shows best percentage changes from baseline in target lesion size for patients treated with nelitolimod 2 mg or 8 mg plus pembrolizumab 200 mg. The plot illustrates the depth of tumor response across both dosing groups.</p> ... Full text Cite

Supplementary Figure S5 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <p>Figure S5 shows Kaplan-Meier curves depicting progression-free survival for patients treated with nelitolimod 2 mg or 8 mg in combination with pembrolizumab 200 mg. The figure illustrates time-to-event data for each dose group.</p> Full text Cite

Data from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <div>AbstractPurpose:<p>Nelitolimod (previously SD-101) is a toll-like receptor 9 agonist. We assessed whether intratumoral nelitolimod plus pembrolizumab potentiates antitumor activity in patients with advanced melanoma who had not pre ... Full text Cite

Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.

Journal Article Cancer Med · October 2025 INTRODUCTION: Enfortumab vedotin-ejfv (EV), an antibody-drug conjugate approved for advanced urothelial carcinoma (aUC), has limited real-world safety data and no validated predictive biomarkers. Retrospective studies suggest higher objective response rate ... Full text Link to item Cite

17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433)

Conference The Oncologist · October 1, 2025 AbstractBackgroundDespite advances in the treatment of metastatic ccRCC, few patients are cured. Therapies exploiting novel targets ar ... Full text Cite

Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.

Journal Article Oncologist · June 4, 2025 BACKGROUND: Anexelokto (AXL) protein and its ligand, growth arrest specific-6 (GAS6), are important drivers of metastasis in patients with advanced clear cell renal cell carcinoma (ccRCC). Batiraxcept competitively binds GAS6 limiting interaction with AXL ... Full text Link to item Cite

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.

Journal Article Prostate Cancer Prostatic Dis · June 2025 BACKGROUND: KEYNOTE-199 (NCT02787005) is a multicohort phase 2 study evaluating pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). Results from cohorts 4 (C4) and 5 (C5) are presented. METHODS: Eligible patients had not ... Full text Link to item Cite

Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer.

Journal Article Eur Urol Oncol · April 2025 BACKGROUND AND OBJECTIVE: Despite curative-intent radical cystectomy (RC), patients with muscle-invasive bladder cancer (MIBC) are at high risk of recurrence. Biomarkers are urgently needed to refine prognostication and selection of appropriate perioperati ... Full text Link to item Cite

Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.

Journal Article Eur Urol Oncol · April 2025 Enfortumab vedotin (EV) is used as monotherapy or combined with pembrolizumab in advanced urothelial carcinoma (aUC), but biomarker data associated with EV outcomes are limited. We identified 170 patients in the UNITE study who received EV monotherapy and ... Full text Link to item Cite

Data from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <div>Abstract<p>High-dose intravenous vitamin C (HDIVC) administered to produce pharmacologic concentrations shows promise in preclinical models and small clinical trials, but larger prospective randomized trials are lacking. We evaluat ... Full text Cite

Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S16 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 4</p> ... Full text Cite

Table S5 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S5 shows AEs with Attribution Possible, Probable or Definite to Treatment (HDVIC or Placebo) listed by types and grades</p> ... Full text Cite

Table S7 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S7 shows Serious Adverse Events (N = 11 patients), by Type and Grade. Attributions Assigned Docetaxel versus HDIVC or Placebo</p> ... Full text Cite

Table S2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S2 shows Association of HDIVC Treatment with PSA Response Adjusting for Prior Docetaxel Exposure</p> ... Full text Cite

Table S10 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S10 shows ANCOVA Least-squares Means for Cycle 4, 6, and 8 FACT-P Total by Study Arm</p> ... Full text Cite

Table S4 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S4 shows Adverse Events Included in the Co-primary Endpoint: Worst Grade by Patient</p> ... Full text Cite

Supplementary Methods from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Supplementary methods include study design and participants, outcomes and statistical analysis, FACT-P questionnaire, pharmacokinetics, and F2-Isoprostanes</p> ... Full text Cite

Table S14 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S14 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 4</p> ... Full text Cite

Table S13 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S13 shows Comparison of F2-Isoprostanes at Baseline between Treatment and Control Arms</p> ... Full text Cite

Table S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6</p> ... Full text Cite

Table S12 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S12 shows Comparison of FACT-P Change Scores Between Study Arms: Mean Difference Docetaxel + HDVIC Minus Docetaxel + Placebo</p> ... Full text Cite

Table S17 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S17 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 6</p> ... Full text Cite

Table S6 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S6 shows AEs with Attribution Possible, Probable or Definite to Docetaxel listed by types and grades</p> ... Full text Cite

Table S1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S1 shows Participating Sites and the Number of Patients Enrolled in the Trial at Each Institution</p> ... Full text Cite

A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).

Conference Journal of Clinical Oncology · February 10, 2025 TPS904Background: Activating FGFR3 gene alterations have been identified i ... Full text Cite

Tumor mutational burden as a marker for radiologic response to immune checkpoint inhibitors.

Journal Article Curr Probl Diagn Radiol · 2025 PURPOSE: This study aimed to evaluate the utility of tumor mutational burden (TMB) as a marker for radiologic response to immune checkpoint inhibitor (ICI) therapy at a single tertiary cancer center. MATERIALS AND METHODS: In this retrospective study, out ... Full text Link to item Cite

Onco-Primary Care of Patients Receiving Immune Checkpoint Inhibitors.

Journal Article Am J Med · December 2024 Primary clinicians foster long-term relationships with patients and play key roles in the treatment journey for patients with cancer. Primary clinicians are important members of the multidisciplinary team and are central in coordinating and providing suppo ... Full text Link to item Cite

Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).

Journal Article J Immunother Cancer · November 20, 2024 BACKGROUND: Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel, engineered cytokine that selectively binds to the intermediate-affinity interleukin-2 receptor, preferentially activating CD8+ T cells and natural killer cells, with minimal expansion of reg ... Full text Open Access Link to item Cite

Table S2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S2 shows Association of HDIVC Treatment with PSA Response Adjusting for Prior Docetaxel Exposure</p> ... Full text Cite

Table S17 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S17 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 6</p> ... Full text Cite

Table S5 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S5 shows AEs with Attribution Possible, Probable or Definite to Treatment (HDVIC or Placebo) listed by types and grades</p> ... Full text Cite

Table S6 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S6 shows AEs with Attribution Possible, Probable or Definite to Docetaxel listed by types and grades</p> ... Full text Cite

Table S12 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S12 shows Comparison of FACT-P Change Scores Between Study Arms: Mean Difference Docetaxel + HDVIC Minus Docetaxel + Placebo</p> ... Full text Cite

Table S14 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S14 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 4</p> ... Full text Cite

Supplementary Methods from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Supplementary methods include study design and participants, outcomes and statistical analysis, FACT-P questionnaire, pharmacokinetics, and F2-Isoprostanes</p> ... Full text Cite

Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S16 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 4</p> ... Full text Cite

Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S16 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 4</p> ... Full text Cite

Table S7 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S7 shows Serious Adverse Events (N = 11 patients), by Type and Grade. Attributions Assigned Docetaxel versus HDIVC or Placebo</p> ... Full text Cite

Table S13 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S13 shows Comparison of F2-Isoprostanes at Baseline between Treatment and Control Arms</p> ... Full text Cite

Data from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <div>Abstract<p>High-dose intravenous vitamin C (HDIVC) administered to produce pharmacologic concentrations shows promise in preclinical models and small clinical trials, but larger prospective randomized trials are lacking. We evaluat ... Full text Cite

Table S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6</p> ... Full text Cite

Table S7 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S7 shows Serious Adverse Events (N = 11 patients), by Type and Grade. Attributions Assigned Docetaxel versus HDIVC or Placebo</p> ... Full text Cite

Table S10 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S10 shows ANCOVA Least-squares Means for Cycle 4, 6, and 8 FACT-P Total by Study Arm</p> ... Full text Cite

Supplementary Methods from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Supplementary methods include study design and participants, outcomes and statistical analysis, FACT-P questionnaire, pharmacokinetics, and F2-Isoprostanes</p> ... Full text Cite

Table S13 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S13 shows Comparison of F2-Isoprostanes at Baseline between Treatment and Control Arms</p> ... Full text Cite

Table S4 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S4 shows Adverse Events Included in the Co-primary Endpoint: Worst Grade by Patient</p> ... Full text Cite

Table S2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S2 shows Association of HDIVC Treatment with PSA Response Adjusting for Prior Docetaxel Exposure</p> ... Full text Cite

Table S4 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S4 shows Adverse Events Included in the Co-primary Endpoint: Worst Grade by Patient</p> ... Full text Cite

Table S6 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S6 shows AEs with Attribution Possible, Probable or Definite to Docetaxel listed by types and grades</p> ... Full text Cite

Table S1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S1 shows Participating Sites and the Number of Patients Enrolled in the Trial at Each Institution</p> ... Full text Cite

Table S12 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S12 shows Comparison of FACT-P Change Scores Between Study Arms: Mean Difference Docetaxel + HDVIC Minus Docetaxel + Placebo</p> ... Full text Cite

Table S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6</p> ... Full text Cite

Table S14 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S14 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 4</p> ... Full text Cite

Table S10 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S10 shows ANCOVA Least-squares Means for Cycle 4, 6, and 8 FACT-P Total by Study Arm</p> ... Full text Cite

Table S5 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S5 shows AEs with Attribution Possible, Probable or Definite to Treatment (HDVIC or Placebo) listed by types and grades</p> ... Full text Cite

Table S17 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S17 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 6</p> ... Full text Cite

Table S1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S1 shows Participating Sites and the Number of Patients Enrolled in the Trial at Each Institution</p> ... Full text Cite

Supplementary Methods from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Supplementary methods include study design and participants, outcomes and statistical analysis, FACT-P questionnaire, pharmacokinetics, and F2-Isoprostanes</p> ... Full text Cite

Supplementary Methods from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Supplementary methods include study design and participants, outcomes and statistical analysis, FACT-P questionnaire, pharmacokinetics, and F2-Isoprostanes</p> ... Full text Cite

Figure 2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Key secondary endpoints. Key secondary endpoints include rPFS, OS, duration of PSA response, and quality of life measured using the FACT-P instrument. <b>A,</b> rPFS and (<b>B</b>) OS are presented for docetaxel + H ... Full text Cite

Figure 1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>CONSORT diagram. The diagram shows eligibility assessment, randomization, allocation, discontinuations, and numbers of subjects analyzed.</p> ... Full text Cite

Table S1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S1 shows Participating Sites and the Number of Patients Enrolled in the Trial at Each Institution</p> ... Full text Cite

Table S17 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S17 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 6</p> ... Full text Cite

Table S2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S2 shows Association of HDIVC Treatment with PSA Response Adjusting for Prior Docetaxel Exposure</p> ... Full text Cite

Table S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6</p> ... Full text Cite

Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S16 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 4</p> ... Full text Cite

Table S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6</p> ... Full text Cite

Table S14 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S14 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 4</p> ... Full text Cite

Data from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <div>Abstract<p>High-dose intravenous vitamin C (HDIVC) administered to produce pharmacologic concentrations shows promise in preclinical models and small clinical trials, but larger prospective randomized trials are lacking. We evaluat ... Full text Cite

Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S16 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 4</p> ... Full text Cite

Table S14 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S14 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 4</p> ... Full text Cite

Table S1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S1 shows Participating Sites and the Number of Patients Enrolled in the Trial at Each Institution</p> ... Full text Cite

Figure 2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Key secondary endpoints. Key secondary endpoints include rPFS, OS, duration of PSA response, and quality of life measured using the FACT-P instrument. <b>A,</b> rPFS and (<b>B</b>) OS are presented for docetaxel + H ... Full text Cite

Table S17 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S17 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 6</p> ... Full text Cite

Table S12 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S12 shows Comparison of FACT-P Change Scores Between Study Arms: Mean Difference Docetaxel + HDVIC Minus Docetaxel + Placebo</p> ... Full text Cite

Table S10 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S10 shows ANCOVA Least-squares Means for Cycle 4, 6, and 8 FACT-P Total by Study Arm</p> ... Full text Cite

Table S12 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S12 shows Comparison of FACT-P Change Scores Between Study Arms: Mean Difference Docetaxel + HDVIC Minus Docetaxel + Placebo</p> ... Full text Cite

Table S13 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S13 shows Comparison of F2-Isoprostanes at Baseline between Treatment and Control Arms</p> ... Full text Cite

Table S13 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S13 shows Comparison of F2-Isoprostanes at Baseline between Treatment and Control Arms</p> ... Full text Cite

Table S10 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S10 shows ANCOVA Least-squares Means for Cycle 4, 6, and 8 FACT-P Total by Study Arm</p> ... Full text Cite

Figure 1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>CONSORT diagram. The diagram shows eligibility assessment, randomization, allocation, discontinuations, and numbers of subjects analyzed.</p> ... Full text Cite

Table S4 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S4 shows Adverse Events Included in the Co-primary Endpoint: Worst Grade by Patient</p> ... Full text Cite

Table S5 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S5 shows AEs with Attribution Possible, Probable or Definite to Treatment (HDVIC or Placebo) listed by types and grades</p> ... Full text Cite

Table S4 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S4 shows Adverse Events Included in the Co-primary Endpoint: Worst Grade by Patient</p> ... Full text Cite

Table S7 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S7 shows Serious Adverse Events (N = 11 patients), by Type and Grade. Attributions Assigned Docetaxel versus HDIVC or Placebo</p> ... Full text Cite

Table S5 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S5 shows AEs with Attribution Possible, Probable or Definite to Treatment (HDVIC or Placebo) listed by types and grades</p> ... Full text Cite

Table S2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S2 shows Association of HDIVC Treatment with PSA Response Adjusting for Prior Docetaxel Exposure</p> ... Full text Cite

Table S6 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S6 shows AEs with Attribution Possible, Probable or Definite to Docetaxel listed by types and grades</p> ... Full text Cite

Table S6 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S6 shows AEs with Attribution Possible, Probable or Definite to Docetaxel listed by types and grades</p> ... Full text Cite

Table S7 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S7 shows Serious Adverse Events (N = 11 patients), by Type and Grade. Attributions Assigned Docetaxel versus HDIVC or Placebo</p> ... Full text Cite

Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.

Journal Article Cancer Lett · August 1, 2024 Older patients have similar immune checkpoint inhibitor efficacy and rates of adverse events as younger patients, but appear to have decreased tolerability, particularly in the oldest patient cohort (>80 years), often leading to early cessation of therapy. ... Full text Link to item Cite

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.

Journal Article Eur Urol Oncol · August 2024 BACKGROUND AND OBJECTIVE: Checkpoint inhibitor therapy (CPI) has demonstrated survival benefits in urothelial carcinoma (UC); however, not all patients benefit from CPI due to resistance. Combining sitravatinib, a multitargeted receptor tyrosine kinase inh ... Full text Link to item Cite

High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial.

Journal Article Cancer Res Commun · August 1, 2024 UNLABELLED: High-dose intravenous vitamin C (HDIVC) administered to produce pharmacologic concentrations shows promise in preclinical models and small clinical trials, but larger prospective randomized trials are lacking. We evaluated the clinical benefit ... Full text Link to item Cite

Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer.

Journal Article Nat Rev Urol · May 2024 Major advances have been made in the use of immunotherapy for the treatment of solid tumours, including the use of intratumourally injected immunotherapy instead of systemically delivered immunotherapy. The success of immunotherapy in prostate cancer treat ... Full text Link to item Cite

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.

Journal Article J Clin Oncol · April 20, 2024 PURPOSE: Locally advanced/metastatic urothelial cancer (la/mUC) affects patients' quality of life (QOL) and functioning. We describe the impact of first-line (1L) enfortumab vedotin (EV) alone or with pembrolizumab (P) on QOL/functioning/symptoms in patien ... Full text Link to item Cite

A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.

Journal Article Future Oncol · March 2024 WHAT IS THIS SUMMARY ABOUT?: This summary provides the results of a study of two treatments for cancer, enfortumab vedotin and pembrolizumab, that were studied together against locally advanced or metastatic urothelial cancer (la/mUC), a cancer that occurs ... Full text Link to item Cite

New phase 1 SURPASS trial cohort: Early-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in urothelial carcinoma.

Conference Journal of Clinical Oncology · February 1, 2024 TPS708Background: ADP-A2M4CD8 T-cell receptor (TCR) T-cell therapy consists of autologous CD4+ and CD8+ T-cells genetically modified to target melanoma-associated antigen A4 (MAGE-A4) in patients (pts) with advanced cancers who are human leukocyte antigen ... Full text Cite

Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study.

Conference Journal of Clinical Oncology · February 1, 2024 537Background: MAv is approved in pts with aUC without progression (PD) on 1L platinum-based therapy (PBT). As pts in the pivotal EV trials had not received MAv after PBT, data on outcomes with EV post-MAv are limited. We examined outcomes with EV post-MAv ... Full text Cite

Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database

Conference Journal of Clinical Oncology · January 1, 2024 Background: The optimal therapy sequencing in aUC with FGFR2/3 alt is unclear. FGFR inhibition may increase Nectin-4 expression. We hypothesized that outcomes with EV would be more favorable when given after E compared to before E in pts with aUC harboring ... Full text Cite

Extended follow-up report of a randomized phase II trial comparing gemcitabine and cisplatin with or without berzosertib in patients with advanced urothelial carcinoma.

Conference Journal of Clinical Oncology · January 1, 2024 Background: Gemcitabine with cisplatin (GC) remains a frontline treatment option for patients (pts) with metastatic urothelial cancer (mUC). Preclinical synergy has been noted when combining cisplatin with berzosertib, a selective ATR inhibitor. This trial ... Full text Cite

Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study

Conference Journal of Clinical Oncology · January 1, 2024 Background: Squamous histology (SH) is the most common variant of Urothelial Carcinoma (UC) and is associated with lower response rates to chemotherapy. The impact of SH on outcomes with enfortumab vedotin (EV) is less defined. We hypothesized that increas ... Full text Cite

Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.

Conference Journal of Clinical Oncology · January 1, 2024 Background: Enfortumab vedotin (EV) is approved for patients (pts) with advanced urothelial carcinoma (aUC) but outcomes in pts with histology variants (HV) have not been well described. We hypothesized that presence of HV would impact EV treatment outcome ... Full text Cite

Assessing the utility of molecular diagnostic classification for cancers of unknown primary.

Journal Article Cancer Med · October 2023 BACKGROUND: Roughly 5% of metastatic cancers present with uncertain origin, for which molecular classification could influence subsequent management; however, prior studies of molecular diagnostic classifiers have reported mixed results with regard to clin ... Full text Link to item Cite

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.

Journal Article J Clin Oncol · September 1, 2023 PURPOSE: Patients with locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible for cisplatin-based therapy have limited first-line (1L) treatment options and significant need for improved therapies. Enfortumab vedotin (EV) and pembroli ... Full text Link to item Cite

Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.

Conference Journal of Clinical Oncology · June 1, 2023 4568 Background: There is a high unmet need for effective and durable first-line (1L) treatment options in cisplatin-ineligible la/mUC. EV and P have shown survival benefit as monotherapies in 2L+ la/mUC, and preclinical studies ... Full text Cite

Randomized placebo-controlled trial of intravenous vitamin C plus docetaxel in metastatic prostate cancer.

Conference Journal of Clinical Oncology · June 1, 2023 e17050 Background: Some phase I/II trials showed that combining high dose IV vitamin C with chemotherapies decreased toxicities and improved QoL in advanced cancers, while others failed to show benefits. While grade ¾ AEs are not ... Full text Cite

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).

Conference Journal of Clinical Oncology · June 1, 2023 4534 Background: AXL is up-regulated by hypoxia-inducible factor-1 signaling in VHL-deficient tumor cells, playing a critical role in metastasis and resistance to VEGF-targeted therapies. Batiraxcept is a recombinant fusion prote ... Full text Cite

Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.

Conference Journal of Clinical Oncology · June 1, 2023 4595 Background: Cisplatin-ineligible pts with MIBC have no established neoadjuvant treatment options known to prolong survival before undergoing radical cystectomy and pelvic lymph node dissection (RC+PLND), Enfortumab vedotin ( ... Full text Cite

Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.

Conference Journal of Clinical Oncology · June 1, 2023 4573 Background: EV is used for treatment-refractory aUC with activity also noted in a frontline trial. Independent biomarkers associated with EV treatment outcomes are lacking. Methods: UNITE is a multi-site retrospective study ... Full text Cite

Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

Conference Journal of Clinical Oncology · June 1, 2023 4505 Background: Despite available therapeutic options, which include carboplatin-based chemotherapy, PD-1/PD-L1 inhibitor monotherapies, and avelumab maintenance, there is an urgent unmet need for effective and durable 1L therap ... Full text Cite

Association of tumor-informed minimal residual disease (MRD) with clinical outcomes for muscle invasive bladder cancer (MIBC): A multicenter retrospective real-world analysis.

Conference Journal of Clinical Oncology · June 1, 2023 3050 Background: Muscle invasive bladder cancer is associated with a significant elevated risk of mortality and morbidity due to micro metastatic spread at the time of diagnosis. Accurate biomarkers to guide treatment determinati ... Full text Cite

Data from Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity

Other · March 31, 2023 <div>Abstract<p>Effective cancer immunotherapy depends on the robust activation of tumor-specific antigen-presenting cells (APC). Immune agonists encapsulated within nanoparticles (NP) can be delivered to tumor sites to generate powerfu ... Full text Cite

Supplementary Data from Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity

Other · March 31, 2023 <p>SF1: IFNβ production from macrophages by ELISA analysis; SF2: FMT imaging of mammary tumors ex vivo for spatial localization of nanoparticle; SF3: Confocal micrographs of DiI-nanoparticle fluorescence in mammary tumor tissue; SF4: Represen ... Full text Cite

Supplementary Data from Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity

Other · March 31, 2023 <p>SF1: IFNβ production from macrophages by ELISA analysis; SF2: FMT imaging of mammary tumors ex vivo for spatial localization of nanoparticle; SF3: Confocal micrographs of DiI-nanoparticle fluorescence in mammary tumor tissue; SF4: Represen ... Full text Cite

Data from Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity

Other · March 31, 2023 <div>Abstract<p>Effective cancer immunotherapy depends on the robust activation of tumor-specific antigen-presenting cells (APC). Immune agonists encapsulated within nanoparticles (NP) can be delivered to tumor sites to generate powerfu ... Full text Cite

Microtubule Agents

Chapter · January 2, 2023 The standard-setting text in oncology for 40 years, DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance and strategies for managing every type of cancer by stage and ... ... Cite

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.

Journal Article J Clin Oncol · January 1, 2023 PURPOSE: Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic urothelial cancer (la/mUC); however, toxicity is substantial, responses are rarely durable, and many patients with la/mUC are ineligible. Each ... Full text Link to item Cite

Outcomes of Antineoplastic Immunotherapy at a Large Healthcare Organization: Impact of Provider, Race and Socioeconomic Status.

Journal Article Cancer Manag Res · 2023 PURPOSE: Disparities in cancer care delivery remain a pressing health-care crisis within the United States (US). The use of immune checkpoint inhibitors (ICIs) and their management may be a disparity generator that impacts survival. This retrospective stud ... Full text Link to item Cite

Minding the Bathwater: Fertility and Reproductive Toxicity in the Age of Immuno-Oncology.

Journal Article JCO Oncol Pract · December 2022 Immune checkpoint inhibition has resulted in significant efficacy across many cancer types, including melanoma. Melanoma is the second most common cancer among those of reproductive age, yet the reproductive toxicities of adjuvant and first-line immunother ... Full text Link to item Cite

Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.

Journal Article Clin Genitourin Cancer · December 2022 BACKGROUND: Early progression on first-line (1L) platinum-based therapy or between therapy lines may be a surrogate of more aggressive disease and poor outcomes in advanced urothelial carcinoma (aUC), but its prognostic role regarding immune checkpoint inh ... Full text Link to item Cite

Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.

Journal Article BJU Int · November 2022 OBJECTIVES: To compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation therapy (RT) prior to developi ... Full text Link to item Cite

Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.

Journal Article Clin Genitourin Cancer · October 2022 BACKGROUND: Sites of metastasis have prognostic significance in advanced urothelial carcinoma (aUC), but more information is needed regarding outcomes based on metastatic sites in patients treated with immune checkpoint inhibitors (ICI). We hypothesized th ... Full text Link to item Cite

Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.

Journal Article Clin Genitourin Cancer · April 2022 BACKGROUND: Immune checkpoint inhibitors (ICI) improve overall survival (OS) in patients with locally advanced, unresectable, or metastatic urothelial carcinoma (aUC), but response rates can be modest. We compared outcomes between patients with and without ... Full text Link to item Cite

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.

Journal Article Cancer · March 15, 2022 BACKGROUND: Enfortumab vedotin (EV) is a novel antibody-drug conjugate approved for advanced urothelial cancer (aUC) refractory to prior therapy. In the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study, the authors looked at t ... Full text Link to item Cite

Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.

Conference Journal of Clinical Oncology · February 20, 2022 435 Background: Up to 25% of all pts diagnosed with urothelial cancer present with muscle-invasive disease for whom the risk of progression or metastasis is substantial. Neoadjuvant chemotherapy prior to radical cystectomy and pe ... Full text Cite

Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).

Conference Journal of Clinical Oncology · February 20, 2022 TPS587 Background: The current standard of care for patients (pts) with newly diagnosed MIBC is neoadjuvant cisplatin (cis)-based chemotherapy followed by radical cystectomy and pelvic lymph node dissection (RC+PLND). For the 20- ... Full text Cite

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.

Journal Article JAMA Oncol · December 1, 2021 IMPORTANCE: Geriatric (aged ≥80 years) patients are historically underrepresented in cancer clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in geriatric patients. These agents are associated with immune-related ad ... Full text Link to item Cite

Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.

Journal Article JAMA Oncol · October 1, 2021 IMPORTANCE: Preclinical studies suggest that inhibition of single-stranded DNA repair by ataxia telangiectasia and Rad3 (ATR) may enhance the cytotoxicity of cisplatin, gemcitabine, and other chemotherapeutic agents. Cisplatin with gemcitabine remains the ... Full text Link to item Cite

Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.

Journal Article AJR Am J Roentgenol · September 2021 BACKGROUND. Patients undergoing immune checkpoint inhibitor (ICI) therapy may present to the emergency department (ED) with a wide range of immune-related adverse events. OBJECTIVE. The purpose of our study was to evaluate chest CT findings in patients rec ... Full text Link to item Cite

High-dose interleukin-2 therapy related adverse events and implications on imaging.

Journal Article Diagn Interv Radiol · September 2021 High-dose interleukin-2 (HDIL-2) therapy was initially approved by the U.S. Food and Drug Administration for metastatic renal cell carcinoma (mRCC) and metastatic melanoma. IL-2 is able to promote CD8+ T cell and natural killer (NK) cell cytotoxicity to in ... Full text Link to item Cite

Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.

Journal Article BJU Int · August 2021 OBJECTIVES: To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). PATIENTS AND METHODS: We performed a ... Full text Link to item Cite

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).

Journal Article J Clin Oncol · August 1, 2021 PURPOSE: The combination of gemcitabine and cisplatin (GC) is a standard therapy for metastatic urothelial carcinoma. Based on data that angiogenesis plays a role in urothelial carcinoma growth and progression, a randomized placebo-controlled trial was per ... Full text Link to item Cite

Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.

Journal Article Future Oncol · August 2021 Muscle-invasive bladder cancer (MIBC) is associated with high rates of recurrence and poor prognosis despite aggressive treatment. Neoadjuvant chemotherapy before radical cystectomy (RC) improves outcomes in cisplatin-eligible patients; however, the improv ... Full text Link to item Cite

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.

Journal Article J Immunother Cancer · July 2021 A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection ... Full text Link to item Cite

A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.

Journal Article Eur Urol Oncol · June 2021 BACKGROUND: While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates remain ... Full text Link to item Cite

Impact of BRAF mutations on outcomes in metastatic melanoma with central nervous system metastases treated with immune checkpoint inhibitors.

Conference Journal of Clinical Oncology · May 20, 2021 e21500 Background: Half of patients (pts) with melanoma (mel) develop central nervous system (CNS) metastases (mets), leading to death in over 90% in the pre-immune checkpoint inhibitor (ICI) era. Overall survival (OS) has improv ... Full text Cite

Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.

Conference Journal of Clinical Oncology · May 20, 2021 e16526 Background: ICIs have altered the therapeutic landscape in pts with aUC and new biomarkers are needed to better predict response and outcomes with ICIs. It is unclear whether demographics, such as race, age, sex and histor ... Full text Cite

Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.

Conference Journal of Clinical Oncology · May 20, 2021 5042 Background: KEYNOTE-199 (NCT02787005) is a multicohort phase 2 study to evaluate pembrolizumab (pembro) in mCRPC. A previous analysis of patients with RECIST-measurable (cohort 4 [C4]) or bone-predominant nonmeasurable (coho ... Full text Cite

KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).

Conference Journal of Clinical Oncology · May 20, 2021 TPS4587 Background: Standard of care for MIBC is neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy and pelvic lymph node dissection (RC+PLND); however, in time, patients experience disease recurrence or prog ... Full text Cite

Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).

Conference Journal of Clinical Oncology · May 20, 2021 4528 Background: Significant unmet need remains for people with cisplatin-ineligible (cis-ineligible) locally advanced or metastatic urothelial carcinoma (la/mUC). In the first-line (1L) setting, carboplatin-based regimens have d ... Full text Cite

A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.

Conference Journal of Clinical Oncology · May 20, 2021 4507 Background: Cisplatin with gemcitabine (CG) remains the standard upfront chemotherapy regimen for metastatic urothelial cancer (mUC). Preclinical synergy was noted between cisplatin and berzosertib, a selective ATR inhibitor ... Full text Cite

Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.

Conference Journal of Clinical Oncology · February 20, 2021 406 Background: Despite anatomical and biological differences, upper and lower tract UC (UTUC; LTUC) are usually managed similarly. Modern era clinical trial data comparing their outcomes with ICI are conflicting. We hypothesized ... Full text Cite

Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer.

Journal Article Cancers (Basel) · January 22, 2021 Metastatic castration-resistant prostate cancer poses a serious clinical problem with poor outcomes and remains a deadly disease. New targeted treatment options are urgently needed. PSMA is highly expressed in prostate cancer and has been an attractive bio ... Full text Link to item Cite

Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma.

Journal Article Bladder Cancer · 2021 BACKGROUND: Outcomes of patients with metastatic urothelial carcinoma (mUC) with early bone metastases (eBM) vs no early bone metastases (nBM) have not thoroughly been described in the age of immuno-oncology. OBJECTIVE: To compare survival and other clinic ... Full text Link to item Cite

Novel therapies are changing treatment paradigms in metastatic prostate cancer.

Journal Article J Hematol Oncol · October 28, 2020 Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients w ... Full text Link to item Cite

Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy.

Journal Article Abdom Radiol (NY) · October 2020 PURPOSE: To determine the frequency, imaging, and clinical manifestations of immune checkpoint inhibitor (ICI)-related colitis in cancer patients on monotherapy or combination therapy. METHODS: The electronic medical records of 1044 cancer patients who rec ... Full text Link to item Cite

Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients.

Journal Article Emerg Radiol · August 2020 Immune checkpoint inhibitor (ICI)-associated myocarditis is a rare but potentially fatal complication associated with development of other immune-related adverse events (irAEs). Troponin levels, ECG, echocardiography, and cardiac MR can assist with the dia ... Full text Link to item Cite

Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.

Journal Article J Urol · July 2020 PURPOSE: Urinary tract cancer can be pure urothelial carcinoma, pure nonurothelial carcinoma or variant urothelial carcinoma (defined here as mixed urothelial carcinoma). Little is known regarding outcomes for patients with variant urothelial carcinoma rec ... Full text Link to item Cite

Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.

Journal Article Cancer · March 15, 2020 BACKGROUND: Immune checkpoint inhibitors (ICIs) represent an appealing treatment for patients with advanced urothelial cancer (aUC) and a poor performance status (PS). However, the benefit of ICIs for patients with a poor PS remains unknown. It was hypothe ... Full text Link to item Cite

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · March 2020 This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non-muscle-invasive urothelial bladder cancer, and treatmen ... Full text Link to item Cite

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.

Journal Article J Clin Oncol · February 10, 2020 PURPOSE: Pembrolizumab has previously shown antitumor activity against programmed death ligand 1 (PD-L1)-positive metastatic castration-resistant prostate cancer (mCRPC). Here, we assessed the antitumor activity and safety of pembrolizumab in three paralle ... Full text Link to item Cite

Systemic Therapies for Melanoma Brain Metastases: A Primer for Radiologists.

Journal Article J Comput Assist Tomogr · 2020 OBJECTIVE: The purpose of this article is to provide a primer for radiologists outlining the modern systemic therapies used in melanoma brain metastases, including tyrosine kinase inhibitors and immune checkpoint inhibitors. The role of radiologic treatmen ... Full text Link to item Cite

Novel MYC-Targeting Drug Is Effective in Mouse Prostate Cancer Models.

Journal Article Cancer Discov · January 2020 A new MYC inhibitor reduced tumor growth in mouse prostate cancer models. ... Full text Link to item Cite

Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience.

Journal Article J Comput Assist Tomogr · 2020 OBJECTIVE: The aim of the study was to study clinical, imaging findings, response patterns, and immune-related adverse events in classical Hodgkin lymphoma (cHL) and non-Hodgkin lymphoma (NHL) patients treated with immune checkpoint inhibitors (ICIs). METH ... Full text Link to item Cite

Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity.

Journal Article Cancer Res · October 15, 2019 Effective cancer immunotherapy depends on the robust activation of tumor-specific antigen-presenting cells (APC). Immune agonists encapsulated within nanoparticles (NP) can be delivered to tumor sites to generate powerful antitumor immune responses with mi ... Full text Link to item Cite

Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).

Journal Article J Clin Oncol · October 10, 2019 PURPOSE: Patients with metastatic urothelial carcinoma are often ineligible for cisplatin-based treatments. A National Cancer Institute Cancer Therapy Evaluation Program-sponsored trial assessed the tolerability and efficacy of a gemcitabine-eribulin combi ... Full text Link to item Cite

Outcomes of patients (pts) with metastatic urothelial cancer (mUC) and poor performance status (PS) receiving anti-PD(L)1 agents.

Conference Journal of Clinical Oncology · May 20, 2019 4525 Background: Anti-PD(L)1 immune checkpoint inhibitors (ICI) prolong overall survival (OS) after platinum chemotherapy in mUC. However, clinical outcomes in pts with poor PS at time of ICI initiation are unknown. We hypothesiz ... Full text Cite

A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.

Journal Article Cancer · April 1, 2019 BACKGROUND: Cluster of differentiation 70 (CD70) is frequently expressed in renal cell carcinoma (RCC) and has immunomodulatory properties. An antibody-drug conjugate targeting CD70, SGN-CD70A, was developed to treat patients with CD70-positive RCC. METHOD ... Full text Link to item Cite

Management of Immunotherapy-Related Toxicities, Version 1.2019.

Journal Article J Natl Compr Canc Netw · March 1, 2019 The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel i ... Full text Link to item Cite

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.

Journal Article Clin Cancer Res · January 1, 2019 PURPOSE: Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may develop de novo or as a mechanism of treatment resistance. N-myc is capable of driving NEPC progression. Alisertib inhibits the interaction between N-myc an ... Full text Link to item Cite

Antimicrotubule agents

Chapter · November 16, 2018 Cite

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.

Journal Article J Immunother Cancer · October 22, 2018 BACKGROUND: We assessed the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC). METHODS: In this phase 1b expansion cohort, patients with mACC ... Full text Open Access Link to item Cite

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.

Journal Article Target Oncol · October 2018 BACKGROUND: The identification of prognostic and/or predictive biomarkers for response to immune checkpoint inhibitors (ICI) could help guide treatment decisions. OBJECTIVE: We assessed changes in programmed cell death-1 (PD1)/PD1 ligand (PDL1) expression ... Full text Link to item Cite

Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy

Journal Article Annals of oncology : official journal of the European Society for Medical Oncology · October 1, 2018 Full text Cite

A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)

Journal Article Annals of oncology : official journal of the European Society for Medical Oncology · October 1, 2018 Full text Cite

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Journal Article J Natl Compr Canc Netw · September 2018 The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 versi ... Full text Link to item Cite

Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.

Journal Article Urol Oncol · September 2018 BACKGROUND: Myeloid derived suppressor cells (MDSC) are heterogeneous immunosuppressive cells with potential predictive and prognostic roles in cancer. The association between MDSC, clinicopathologic factors, and pathologic response in patients with bladde ... Full text Link to item Cite

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

Journal Article Cancer · May 15, 2018 BACKGROUND: Biomarker-guided clinical trials are increasingly common in metastatic urothelial carcinoma (mUC), yet patients for whom contemporary tumor tissue is not available are not eligible. Technological advancements in sequencing have made cell-free c ... Full text Link to item Cite

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).

Journal Article Br J Cancer · May 2018 BACKGROUND: A randomised study to assess the addition of apatorsen, an antisense oligonucleotide that inhibits Hsp27 expression, to docetaxel in patients with metastatic urothelial carcinoma (mUC) relapsed after prior platinum-based chemotherapy. METHODS: ... Full text Link to item Cite

Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.

Journal Article Am J Otolaryngol · 2018 BACKGROUND: We present a case of myositis and possible overlapping neuromuscular junction disorder following treatment with nivolumab for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). METHODS: We report a 75-year-old man with recurren ... Full text Link to item Cite

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · October 2017 This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recomm ... Full text Link to item Cite

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

Journal Article JAMA Oncol · September 14, 2017 IMPORTANCE: The data reported herein were accepted for assessment by the US Food and Drug Administration for Biologics License Application under priority review to establish the clinical benefit of durvalumab as second-line therapy for locally advanced or ... Full text Link to item Cite

NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

Journal Article J Natl Compr Canc Netw · October 2016 These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of int ... Full text Link to item Cite

Radiomics Analysis on FLT-PET/MRI for Characterization of Early Treatment Response in Renal Cell Carcinoma: A Proof-of-Concept Study.

Journal Article Transl Oncol · April 2016 Studying early response to cancer treatment is significant for patient treatment stratification and follow-up. Although recent advances in positron emission tomography (PET) and magnetic resonance imaging (MRI) allow for evaluation of tumor response, a qua ... Full text Link to item Cite

Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based Cohort.

Journal Article Urology · April 2016 OBJECTIVE: To assess the national utilization of partial nephrectomy (PN) for T1a renal masses across different racial groups by hospital type. Although clinical guidelines recommend PN for small renal masses (SRMs), racial disparities persist in the use o ... Full text Link to item Cite

Editorial Comment.

Journal Article Urology · February 2016 Full text Link to item Cite

Antimicrotubule Agents

Chapter · January 1, 2016 Cite

Antimicrotubule Agents

Chapter · January 1, 2016 Cite

Characteristics and Survival of Malignant Cardiac Tumors: A 40-Year Analysis of >500 Patients.

Journal Article Circulation · December 22, 2015 BACKGROUND: The aim of this study was to investigate the incidence, histopathology, demographics, and survival associated with primary malignant cardiac tumors (PMCTs). METHODS AND RESULTS: We queried the Surveillance, Epidemiology and End Results (SEER) 1 ... Full text Link to item Cite

Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle.

Journal Article Cancer Res · April 1, 2015 Glioblastoma multiforme is generally recalcitrant to current surgical and local radiotherapeutic approaches. Moreover, systemic chemotherapeutic approaches are impeded by the blood-tumor barrier. To circumvent limitations in the latter area, we developed a ... Full text Link to item Cite

Antimicrotubule agents

Chapter · January 7, 2015 Cite

Targeted nanotechnology for cancer imaging.

Journal Article Adv Drug Deliv Rev · September 30, 2014 Targeted nanoparticle imaging agents provide many benefits and new opportunities to facilitate accurate diagnosis of cancer and significantly impact patient outcome. Due to the highly engineerable nature of nanotechnology, targeted nanoparticles exhibit si ... Full text Link to item Cite

The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles.

Journal Article Biomaterials · August 2014 A key attribute for nanoparticles (NPs) that are used in medicine is the ability to avoid rapid uptake by phagocytic cells in the liver and other tissues. Poly(ethylene glycol) (PEG) coatings has been the gold standard in this regard for several decades. H ... Full text Link to item Cite

Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.

Journal Article Nanomedicine · November 2013 UNLABELLED: Nearly 40% of patients with non-invasive bladder cancer will progress to invasive disease despite locally-directed therapy. Overcoming the bladder permeability barrier (BPB) is a challenge for intravesical drug delivery. Using the fluorophore c ... Full text Link to item Cite

Systemic therapy for advanced prostate cancer

Chapter · December 1, 2012 Over fifty years after it was first used, androgen deprivation therapy (ADT) is still the mainstay for first line treatment. Unfortunately, the response to ADT is usually limited as the cancer develops an increasing profile of castrate resistant cells. App ... Cite

Surface modified poly(β amino ester)-containing nanoparticles for plasmid DNA delivery.

Journal Article J Control Release · November 28, 2012 The use of biodegradable polymers provides a potentially safe and effective alternative to viral and liposomal vectors for the delivery of plasmid DNA to cells for gene therapy applications. In this work we describe the formulation of a novel nanoparticle ... Full text Link to item Cite

Redefining hormone resistance in prostate cancer.

Journal Article Ther Adv Med Oncol · March 1, 2010 Prostate cancer relies on signaling through the androgen receptor (AR) for maintenance and progression; and androgen-deprivation therapy remains a cornerstone of treatment for advanced prostate cancer. An effective clinical classification of prostate cance ... Full text Link to item Cite

Hodgkin's lymphoma of the breast.

Journal Article J Clin Oncol · January 10, 2010 Full text Link to item Cite

Pancreatic cancer and personalized medicine: Can genomics facilitate early diagnosis or improve therapeutic outcomes?

Journal Article Current Pharmacogenomics and Personalized Medicine · January 1, 2010 Despite recent advances in diagnosis and treatment of certain cancers such as breast, colon and prostate cancers, pancreatic cancer remains a deadly malignancy with a mortality rate almost equal to its incidence. The survival benefit after all possible med ... Full text Cite

Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512).

Journal Article Expert Opin Investig Drugs · September 2009 INTRODUCTION: Fluoropyrimidines with oxaliplatin or irinotecan plus bevacizumab is the standard chemotherapy combination in patients with advanced colorectal cancer (CRC). Gemcitabine acts synergistically with fluoropyrimidines to enhance the binding of th ... Full text Link to item Cite

Biomarkers for early detection and screening in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.

Journal Article JOP · July 6, 2009 Pancreatic cancer is the second most frequent gastrointestinal malignancy with an unabated mortality that reflects the advanced stage of presentation. Detection of early disease through screening likely is the best way to meaningfully prolong survival. The ... Link to item Cite

Pancreatic cancer: translating lessons from mouse models.

Journal Article JOP · March 9, 2009 Pancreatic cancer is the 10th most common cancer and 4th cause of cancer related deaths. Progress in diagnosis and treatment has been slow and disappointing but improvement in understanding of pathogenesis and of molecular changes may offer some ground for ... Link to item Cite

Therapeutic tools in pancreatic cancer.

Journal Article JOP · March 9, 2009 Pancreatic cancer is the fourth leading cause of cancer death in the United States and has a lower survival rate than other digestive tract tumors. It remains a therapeutic challenge with limited active agents. Honing our current understanding of markers o ... Link to item Cite